Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51300 | 0.86 | DRD2 (0.56) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL7901592 | 0.81 | HSD11B1 (0.41) | HTR1ADRD2 | |
| SCHEMBL7907814 | 0.81 | HSD11B1 (0.41) | HTR1ADRD2 | |
| SCHEMBL51088 | 0.80 | HTR1A (0.50) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL15382577 | 0.80 | HTR1A (0.50) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL13851908 | 0.80 | HTR1A (0.50) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL50627 | 0.80 | HTR1A (0.50) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL15382601 | 0.80 | HTR1A (0.50) | HTR1ADRD2CYP3A4F3SIGMAR1 | |
| SCHEMBL7901664 | 0.80 | DRD2 (0.39) | HTR1ADRD2 | |
| SCHEMBL50763 | 0.77 | HSD11B1 (0.39) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HTR1A 210/4885DRD2 184/4885CYP3A4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.